October 25, 2005, Troy, NY--The expansion of a company's sales force is typically not headline news. But if the company is a developer of quantum-dot (QD) nanomaterials, then such an expansion warrants mention, as it denotes the solid commercial potential of QD technology. Evident Technologies Inc., a developer of advanced QD nanomaterials, has added a top sales executive and expanded both its own sales force and its global distribution network.
"To meet the growing demands for all of our nanomaterial products, we have added a new vice president for sales, Jeffrey Goronkin, who has extensive business-development and sales experience in the life science field," said Clinton Ballinger, Evident's CEO.
Currently, Evident has six major product lines in development or on the market for commercial sales. These products--dots, resins, particles, powders, tags, and fluorescing probes--have applications across a number of markets. In addition, the company recently announced the release of its new non-heavy-metal quantum dot T2-MP EviTags.
Evident's T2-MP EviTag product line is based on a version of indium gallium phosphide QDs that are coated with an outer layer of zinc sulphide deposited via Evident's so-called "molecular plating" technique. The presence of this outer protective layer produces a bright, stable, non-heavy-metal QD-based fluorescent label with reduced toxicity that can be useful in applications from clinical diagnostics to cell microscopy, in-vivo imaging, and biothreat detection. The QDs can be used in a broad spectrum of optoelectronic applications such as solar cells, flat-panel displays, and light-emitting diodes. Because they do not contain cadmium or lead--which are found in traditional quantum dots--they are not subject to the restrictions that Japan and European countries have imposed on the use of heavy metals, particularly for consumer devices.
Jeffrey Goronkin has previous experience in the tech medical field. Prior to joining Evident, he was senior commercial manager for Proligo, LLC, a Degussa company, where he rebuilt the sales organization prior to its acquisition by Sigma-Aldrich. At Proligo, Goronkin was also responsible for securing phosphoramidite business for applications in the synthetic DNA/RNA research and therapeutic industries. Before joining Proligo, Goronkin was manager of corporate development for Integrated DNA Technologies, where he was responsible for new-business opportunities in the oligonucleotide market. Goronkin has a bachelor's degree in biology from the University of Arizona.
Ballinger notes that Evident has also tripled its sales staff and added regional sales representatives in targeted areas of the U.S.